Compounds > 2-oxoquazepam
Page last updated: 2024-12-07

2-oxoquazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-oxoquazepam: quazepam metabolite; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID93250
SCHEMBL ID5379874
MeSH IDM0117272

Synonyms (27)

Synonym
PDSP2_001762
PDSP1_001779
49606-44-2
FT-0656739
7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3h-1,4-benzodiazepin-2-one
bdbm81952
2-oxoquazepam
nsc_93250
cas_93250
7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepin-2-one
einecs 256-396-2
8t62s796k7 ,
unii-8t62s796k7
2h-1,4-benzodiazepin-2-one,7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-
AKOS015889819
7-chloro-1,3-dihydro-1-(2,2,2-trifluoroethyl)-5-(2'-fluorophenyl)-2h-1,4-benzodiazepin-2-one
SCHEMBL5379874
sch 15725
2h-1,4-benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-
sch-15725
7-chloro-1-(2,2,2-trifluoroethyl)-1,3-dihydro-5-(2-fluorophenyl)-2h-1,4-benzodiazepin-2-one
oxoquazepam
DTXSID30197932
2-desthio-2-oxo selapam
Q27270983
7-chloro-1-(2,2,2-trifluoroethyl)-5-(2-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepine-2-one
PD094013

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Quazepam and flurazepam share pharmacokinetic properties that result in prevention of early-morning insomnia, daytime rebound anxiety, and withdrawal rebound insomnia."( Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics.
Battista, D; Hilbert, JM, 1991)		0.28
"To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers."( Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam.
Kauert, G; Klausnitzer, W; Schaffler, K; Wauschkuhn, CH, 1989)		0.28
" The method was applied to sublingual pharmacokinetic studies of quazepam in healthy volunteers."( Liquid chromatographic assay and pharmacokinetics of quazepam and its metabolites following sublingual administration of quazepam.
Ellinwood, EH; Gupta, SK, 1988)		0.27
" Therefore, the authors measured and compared pharmacokinetic parameters of quazepam taken in a fasted state and taken 30 minutes after consuming meals containing different amounts of dietary fat."( Effect of dietary fat content in meals on pharmacokinetics of quazepam.
Kaneko, S; Kondo, T; Mihara, K; Ono, S; Takahata, T; Tateishi, T; Yasui-Furukori, N, 2002)		0.31

Dosage Studied

ExcerptRelevanceReference
" In hamsters, 66-77% of the radioactivity was excreted within 48 hr, and 97% within 7 days of dosing (57% found in urine and 40% in feces after iv; 54% in urine and 43% in feces after po dosing)."( The disposition and metabolism of a hypnotic benzodiazepine, quazepam, in the hamster and mouse.
Hilbert, J; Pramanik, B; Symchowicz, S; Zampaglione, N, )		0.13
"Previous metabolic studies have established that two major metabolites, 2-oxoquazepam and N-desalkyl-2-oxoquazepam, are present in plasma after dosing with quazepam, a new benzodiazepine hypnotic."( Excretion of quazepam into human breast milk.
Gural, RP; Hilbert, JM; Symchowicz, S; Zampaglione, N, 1984)		0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (65.38)18.7374
1990's4 (15.38)18.2507
2000's3 (11.54)29.6817
2010's2 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.34%)5.53%
Reviews3 (10.34%)6.00%
Case Studies1 (3.45%)4.05%
Observational0 (0.00%)0.25%
Other22 (75.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.6630amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9710halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
alpha-hydroxytriazolam
alpha-hydroxytriazolam: triazolam metabolite; structure in first source		2.0810triazolobenzodiazepine
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		3.22601,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		6.161011,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
cm 7116
norflutoprazepam: structure		6.16101benzodiazepine
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		1.9710barbituratesGABAA receptor agonist
sch 16134
quazepam: structure given in first source		8.48183benzodiazepine
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		3.8421triazolobenzodiazepinesedative
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		3.411aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
beta-carboline-3-carboxylic acid ethyl ester
beta-carboline-3-carboxylic acid ethyl ester: isolated from brain tissue & urine; extremely potent displacer of diazepam from brain benzodiazepam receptors; structure in first source		2.3720beta-carbolines
cl 218872
CL 218872: shows specific action on benzodiazepine receptors; structure		1.9610pyridazines;
ring assembly
ConditionIndicatedRelationship StrengthStudiesTrials
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9610
Chronic Insomnia
[description not available]		03.7720
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		03.7720
Drug Withdrawal Symptoms
[description not available]		01.9710
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		01.9710